Futibatinib for <i>FGFR2</i> -Rearranged Intrahepatic CholangiocarcinomaLipika Goyal, John Bridgewater, Funda Meric‐Bernstam et al.|New England Journal of Medicine|2023Cited by 530
Feasibility and utility of a panel testing for 114 cancer‐associated genes in a clinical setting: A hospital‐based studyKuniko Sunami, Takashi Kohno, Hitoshi Ichikawa et al.|Cancer Science|2019Cited by 375
Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studiesYoshiaki Nakamura, Takayuki Yoshino, Hiroya Taniguchi et al.|Nature Medicine|2020Cited by 366
Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trialChigusa Morizane, Junji Furuse, Takuji Okusaka et al.|Annals of Oncology|2019Cited by 333
Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 studyMakoto Ueno, Junji Furuse, Masafumi Ikeda et al.|The Lancet. Gastroenterology & hepatology|2019Cited by 331